Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms

Ever since Akkermansia muciniphila was discovered and characterized two decades ago, numerous studies have shown that the lack or decreased abundance of this commensal bacterium was linked with multiple diseases (such as obesity, diabetes, liver steatosis, inflammation and response to cancer immunotherapies). Although primarily based on simple associations, there are nowadays an increasing number of studies moving from correlations to causality. The causal evidence derived from a variety of animal models performed in different laboratories and recently was also recapitulated in a human proof-of-concept trial. In this Review, we cover the history of the discovery of A. muciniphila and summarize the numerous findings and main mechanisms of action by which this intestinal symbiont improves health. A comparison of this microorganism with other next-generation beneficial microorganisms that are being developed is also made. This Review covers the discovery of Akkermansia muciniphila and its association with health and disease, including metabolic diseases. Insights into underlying mechanisms for how A. muciniphila improves health are given as are comparisons with other next-generation beneficial microorganisms.

Automated summary

This article reviews the discovery of Akkermansia muciniphila and its association with health and disease. Studies have shown that A. muciniphila can improve health through various mechanisms and comparisons are made with other next-generation beneficial microorganisms.